Background Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infections (ALRI) among under-5 ...
VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from ...
The Kansas wastewater monitoring program has a new KDHE dashboard where you can see respiratory virus trends in Topeka for ...
As the colder weather months begin, respiratory viruses like the common cold, the flu, RSV and COVID-19, become more ...
7d
NanoViricides, Inc. Has Filed its Quarterly Report – Subsequent Raise Has Fortified Fiscal Position
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...
Nirsevimab was found to be 80% effective at preventing respiratory syncytial virus-associated intensive care unit admissions during the 2024-2025 RSV season, according to a Centers for Disease Control ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of ...
Posters will be available to view on the conference platform during the conference and on the Company’s website here after presentations. Further information about IDWeek™ 2025 can be found here.
There is no drug for treatment of MPox at present. Tecovirimat failed in clinical trials for the treatment of MPox [1], [2]. Brincidofovir entered clinical trials for MPox in January, 2025, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback